Johnson & Johnson $JNJ Shares Sold by Conning Inc.

Conning Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 8.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 141,649 shares of the company’s stock after selling 13,144 shares during the quarter. Conning Inc.’s holdings in Johnson & Johnson were worth $34,625,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of JNJ. Mascoma Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 8.0% in the 1st quarter. Mascoma Wealth Management LLC now owns 1,226 shares of the company’s stock valued at $300,000 after purchasing an additional 91 shares in the last quarter. Relyea Zuckerberg Hanson LLC grew its stake in shares of Johnson & Johnson by 9.2% during the first quarter. Relyea Zuckerberg Hanson LLC now owns 34,418 shares of the company’s stock worth $8,413,000 after purchasing an additional 2,890 shares in the last quarter. Walled Lake Planning & Wealth Management LLC grew its stake in shares of Johnson & Johnson by 22.6% during the first quarter. Walled Lake Planning & Wealth Management LLC now owns 1,988 shares of the company’s stock worth $486,000 after purchasing an additional 367 shares in the last quarter. KLCM Advisors Inc. increased its holdings in Johnson & Johnson by 7.9% in the first quarter. KLCM Advisors Inc. now owns 8,667 shares of the company’s stock valued at $2,119,000 after buying an additional 631 shares during the last quarter. Finally, Cedar Mountain Advisors LLC raised its stake in Johnson & Johnson by 26.3% in the first quarter. Cedar Mountain Advisors LLC now owns 470 shares of the company’s stock valued at $115,000 after buying an additional 98 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.1%

Johnson & Johnson stock opened at $257.17 on Monday. Johnson & Johnson has a fifty-two week low of $154.80 and a fifty-two week high of $269.43. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market capitalization of $619.07 billion, a P/E ratio of 29.73, a PEG ratio of 2.51 and a beta of 0.24. The stock has a 50-day simple moving average of $237.07 and a 200-day simple moving average of $233.23.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The firm had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities research analysts expect that Johnson & Johnson will post 11.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend was Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio is presently 61.97%.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Bank of America raised its price target on Johnson & Johnson to $263 from $254, signaling continued support for the stock even as the firm kept a neutral rating. Benzinga report on the price target increase
• Positive Sentiment: Johnson & Johnson backed a new heart failure device trial, keeping investor focus on its medtech pipeline and longer-term growth opportunities in electrophysiology and cardiovascular care. JNJ Backs New Heart Failure Device Trial
• Positive Sentiment: Analysts continued to highlight JNJ as a strong dividend and defensive healthcare name, with several notes pointing to the company’s earnings consistency and attractive income profile. TipRanks dividend aristocrat article
• Neutral Sentiment: Investors are also looking ahead to J&J’s upcoming Q2 earnings report, with previews suggesting the company may again beat expectations, but the market is still waiting for actual results. Zacks Q2 earnings preview
• Negative Sentiment: An Illinois appellate court affirmed a $45 million mesothelioma verdict against Johnson & Johnson and Kenvue tied to talc-related asbestos allegations, renewing legal risk concerns that can weigh on the shares. Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue

Analyst Ratings Changes

A number of brokerages have issued reports on JNJ. Raymond James Financial lifted their price target on Johnson & Johnson from $237.00 to $258.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Argus raised their target price on Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Johnson Rice set a $270.00 target price on Johnson & Johnson in a research note on Friday, June 26th. Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target on the stock in a research note on Wednesday, May 13th. Finally, HSBC set a $290.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, July 6th. Twenty investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $258.13.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.